NasdaqGS - Nasdaq Real Time Price ? USD NovoCure Limited (NVCR) Follow Compare 17.09 +0.23 (+1.36%) At close: November 21 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Novocure secures FDA approval for add-ons to brain cancer treatment wearable Novocure has refined the transducer arrays that attach to Optune Gio, its wearable for glioblastoma treatment. Medical Device Network ? 17 hours ago NVCR +1.36% Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma ROOT, Switzerland, November 21, 2024--Novocure data at 2024 SNO annual meeting highlights product innovation and real-world evidence for TTFields therapy in glioblastoma. Business Wire ? 21 hours ago NVCR +1.36% FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio? for Glioblastoma ROOT, Switzerland, November 21, 2024--FDA approves Novocure’s Innovative HFE transducer arrays for use with Optune Gio? for glioblastoma. Business Wire ? 22 hours ago NVCR +1.36% NovoCure’s Strong Q3 and Leadership Changes in 2024 NovoCure ( (NVCR) ) just unveiled an announcement. Novocure reported a robust third quarter in 2024, with net revenues surging by 22% to $155 million, driven by successful market expansions and improved approval rates in the U.S. The company also celebrated FDA approval of Optune Lua for metastatic non-small cell lung cancer, marking a significant milestone. Additionally, management transitions are underway with Christoph Brackmann taking over as CFO from January 2025, as Novocure aims to sustai TipRanks ? 21 days ago NVCR +1.36% NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... NovoCure Ltd (NVCR) reports a 22% revenue increase and FDA approvals, while navigating executive changes and reimbursement challenges. GuruFocus.com ? 22 days ago NVCR +1.36% NovoCure (NVCR) Q3 2024 Earnings Call Transcript NVCR earnings call for the period ending September 30, 2024. Motley Fool ? 22 days ago NVCR +1.36% NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates NovoCure (NVCR) delivered earnings and revenue surprises of 17.65% and 7.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 22 days ago NVCR +1.36% NovoCure: Q3 Earnings Snapshot ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Wednesday reported a loss of $30.6 million in its third quarter. The St. Helier, Jersey-based company said it had a loss of 28 cents per share. Associated Press Finance ? 22 days ago NVCR +1.36% Novocure Appoints Christoph Brackmann as Chief Financial Officer ROOT, Switzerland, October 30, 2024--Novocure Appoints Christoph Brackmann as Chief Financial Officer Business Wire ? 22 days ago NVCR +1.36% Novocure Reports Third Quarter 2024 Financial Results ROOT, Switzerland, October 30, 2024--Novocure Reports Third Quarter 2024 Financial Results Business Wire ? 22 days ago NVCR +1.36% Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment Innovative Cancer Treatment Gains Regulatory Approval GuruFocus.com ? last month NVCR +1.36% NovoCure scoops FDA approval on wearable for metastatic cancer treatment Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS improvement. Clinical Trials Arena ? last month NVCR +1.36% Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device. Investor's Business Daily ? last month NVCR +1.36% BMY CELG-RT Novocure wins FDA approval for electric field device in lung cancer Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial. BioPharma Dive ? last month NVCR +1.36% FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. Optune Lua is a portable device that produces alternating electric fields known as tumor-treating fields (TTFields), delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing Benzinga ? last month NVCR +1.36% Novocure shares soar 33% as FDA approves lung cancer treatment Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. Investing.com ? last month NVCR +1.36% NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? last month NVCR +1.36% LCTX FDA Approves Novocure’s Optune Lua? for the Treatment of Metastatic Non-Small Cell Lung Cancer ROOT, Switzerland, October 15, 2024--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua? for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. Business Wire ? last month NVCR +1.36% Novocure to Report Third Quarter 2024 Financial Results ROOT, Switzerland, October 01, 2024--Novocure will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Business Wire ? last month NVCR +1.36% Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy ROOT, Switzerland, September 09, 2024--Novocure to Present Real-World Data at ESMO 2024 Business Wire ? 2 months ago NVCR +1.36% Performance Overview Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return NVCR S&P 500 YTD +14.47% +24.72% 1-Year +40.20% +30.82% 3-Year -83.49% +26.62%
